Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 May;27(21):2101104.
doi: 10.2807/1560-7917.ES.2022.27.21.2101104.

Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

Esther Kissling  1 , Mariëtte Hooiveld  2 , Iván Martínez-Baz  3   4 , Clara Mazagatos  4   5 , Naoma William  6 , Ana-Maria Vilcu  7 , Marjolein N Kooijman  8 , Maja Ilić  9 , Lisa Domegan  10 , Ausenda Machado  11 , Simon de Lusignan  12   13 , Mihaela Lazar  14 , Adam Meijer  8 , Mia Brytting  15 , Itziar Casado  3   4 , Amparo Larrauri  4   5 , Josephine-L K Murray  6 , Sylvie Behillil  16   17 , Brechje de Gier  8 , Ivan Mlinarić  9 , Joan O'Donnell  10 , Ana Paula Rodrigues  11 , Ruby Tsang  12   13 , Olivia Timnea  14 , Marit de Lange  8 , Maximilian Riess  15 , Jesús Castilla  3   4 , Francisco Pozo  18 , Mark Hamilton  6 , Alessandra Falchi  19 , Mirjam J Knol  8 , Sanja Kurečić Filipović  9 , Linda Dunford  20 , Raquel Guiomar  11 , Jade Cogdale  21 , Carmen Cherciu  14 , Tessa Jansen  2 , Theresa Enkirch  15 , Luca Basile  22   4 , Jeff Connell  20 , Verónica Gomez  11 , Virginia Sandonis Martín  18 , Sabrina Bacci  23 , Angela Mc Rose  1 , Lucia Pastore Celentano  23 , Marta Valenciano  1 ; I-MOVE-COVID-19 and ECDC primary care study teams  24 ; I-MOVE-COVID-19 and ECDC primary care study team (in addition to authors above)
Collaborators, Affiliations
Multicenter Study

Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

Esther Kissling et al. Euro Surveill. 2022 May.

Abstract

IntroductionIn July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe.AimUsing a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection.MethodsIndividuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination.ResultsOverall VE was 74% (95% CI: 69-79), 76% (95% CI: 71-80), 63% (95% CI: 48-75) and 63% (95% CI: 16-83) among those aged 30-44, 45-59, 60-74 and ≥ 75 years, respectively. VE among those aged 30-59 years was 78% (95% CI: 75-81), 66% (95% CI: 58-73), 91% (95% CI: 87-94) and 52% (95% CI: 40-61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52-77), 65% (95% CI: 48-76) and 83% (95% CI: 64-92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30-59 years was 87% (95% CI: 83-89) at 14-29 days and 65% (95% CI: 56-71%) at ≥ 90 days between vaccination and onset of symptoms.ConclusionsVE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.

Keywords: COVID-19; Delta variant; Europe; SARS-CoV-2; multicentre study; test-negative design; vaccine effectiveness.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: Professor de Lusignan has received grants not directly relating to this work, from AstraZeneca, GSK, Sanofi, Seqirus and Takeda for vaccine-related research and has been a member of advisory boards for AstraZeneca, Sanofi and Seqirus.

Figures

Figure 1
Figure 1
Countries and study sites taking part in the I-MOVE-COVID-19 and ECDC studies on COVID-19 vaccine effectiveness at primary care/community level, Europe, July–August 2021 (n = 14 sites)
Figure 2
Figure 2
Number of cases and controls by week of swab, and by week of complete COVID-19 vaccination, I-MOVE-COVID-19 and ECDC primary care and community multicentre networks, Europe, July–August 2021 (n = 14,282)
Figure 3
Figure 3
Effectiveness of Comirnaty vaccination among participants in the primary care/community I-MOVE-COVID-19 and ECDC vaccine effectiveness study by days between dose of complete vaccine and onset of symptoms and by age group, Europe, July–August 2021 (n = 10,370)
See this image and copyright information in PMC

References

    1. World Health Organisation (WHO). COVID-19 Weekly Epidemiological Update. Edition 56. Geneva: WHO; 2021. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/2...
    1. European Centre for Disease Prevention and Control (ECDC), World Health Organization Regional Office for Europe (WHO/Europe). Assessing SARS-CoV-2 circulation, variants of concern, non-pharmaceutical interventions and vaccine rollout in the EU/EEA, 16th update. Stockholm: ECDC; 2021. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-...
    1. Nextstrain. Genomic epidemiology of SARS-CoV-2 with Europe-focused subsampling. [Accessed: 30 Oct 2021]. Available from: https://nextstrain.org/ncov/gisaid/europe
    1. Shu Y, McCauley J. GISAID: Global initiative on sharing all influenza data - from vision to reality. Euro Surveill. 2017;22(13):30494. 10.2807/1560-7917.ES.2017.22.13.30494 - DOI - PMC - PubMed
    1. European Medicines Agency (EMA). COVID-19 vaccines: authorised. Amsterdam: EMA. [Accessed: 28 Apr 2022]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-thr... vaccines

Publication types

Supplementary concepts